Business
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON,
About this update from Pulmatrix, Inc.
[{"type":"text","content":"Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine\nLEXINGTON, Mass., May 24, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced that management will present at the annual Biotechnology Innovation Organization (BIO) International Convention, to be held in-person in Boston, MA, June 5 - 8, 2023. Presentation details are below. Pulmatrix management will also be available for one-on-one meetings throughout the conference. \n\n \n \n \n \n \n \n\n \nBIO International Convention Presentation Information:\nFormat: Live presentationPresenter: Ted Raad, Chief Executive Officer, Pulmatrix, Inc.Date: Monday, June 5, 2023Time: 12:45 PM EDTLocation: Room 104A\nFollowing the live presentation at BIO on June 5th, the presentation will be posted here on Pulmatrix's website. \nAbout the PresentationThe presentation will focus on PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. In a recently completed Phase 1 study, PUR3100 demonstrated, at all doses, a Cmax in the target range for systemic exposure and a higher Cmax than the published Cmax data for all other non-IV DHE products. The Tmax achieved at five minutes was also earlier than Tmax data for all non-IV DHE products that has been published to date. Based on this data, Pulmatrix believes that PUR3100 has the potential to meet the significant unmet needs of patients suffering from acute migraine whose treatment options are limited to currently available therapies. \nPulmatrix plans to submit an IND in mid-2023 for a randomized, placebo-controlled, Phase 2 clinical study of PUR3100 in patients with acute migraine. The Phase 2 study would assess the safety and effectiveness of two dose levels of PUR3100. Pulmatrix is actively pursuing partnership opportunities in order to complete the Phase 2 study.\nMeet with ManagementTo set up a meeting with management, please register through the conference meeting platform via the BIO International Convention website here.\nAbout the BIO International ConventionBIO is the world's largest trade associ...